International Prospective Registry on Local Treatment Approaches in MLS

NCT04699292 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-08-30

No results posted yet for this study

Summary

To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)

Conditions

  • Myxoid Liposarcoma

Interventions

PROCEDURE

Surgery

Surgery

RADIATION

Preoperative RT 36Gy

Preoperative radiotherapy to 36Gy (equivalent)

RADIATION

Preoperative RT 50Gy

Preoperative radiotherapy to 50Gy (equivalent)

RADIATION

Postoperative RT 50-66Gy

Postoperative radiotherapy to 50-66Gy (equivalent)

RADIATION

RT 36Gy

Definitive radiotherapy to 36Gy (equivalent)

Sponsors & Collaborators

  • Radboud University Medical Center

    collaborator OTHER
  • Maastro Clinic, The Netherlands

    collaborator OTHER
  • University Medical Center Groningen

    collaborator OTHER
  • Leiden University Medical Center

    collaborator OTHER
  • Vienna General Hospital

    collaborator OTHER
  • M.D. Anderson Cancer Center

    collaborator OTHER
  • University Hospital, Antwerp

    collaborator OTHER
  • Universitetssykehus

    collaborator UNKNOWN
  • Haukeland University Hospital

    collaborator OTHER
  • Universitäts-Frauenklinik Graz

    collaborator OTHER
  • University Hospital Heidelberg

    collaborator OTHER
  • Mayo Clinic

    collaborator OTHER
  • Aarhus University Hospital

    collaborator OTHER
  • National Cancer Center, Japan

    collaborator OTHER_GOV
  • Princess Margaret Hospital, Canada

    collaborator OTHER
  • MOUNT SINAI HOSPITAL

    collaborator OTHER
  • University of Sydney

    collaborator OTHER
  • Institute for Cancer Research and treatment

    collaborator UNKNOWN
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    collaborator OTHER
  • Institut Curie

    collaborator OTHER
  • ANZSA (Australia and New Zealand Sarcoma Association)

    collaborator UNKNOWN
  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Rick Haas, MD/PhD · The Netherlands Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2031-01-31
Completion
2031-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04699292 on ClinicalTrials.gov